Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.ARMP · Entity 6329 | SVP, Finance, and PFO | March 09, 2026 | March 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Armata Pharmaceuticals, Inc.
Report date March 09, 2026 · Filed March 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.61 · Expires 2036-03-09 | Direct | 109,885 |
Reported balance
After 2026-03-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-09 · Grant · Acquired 109,885 · Balance 109,885 F1: Twenty-five percent (25%) of the Stock Options shall vest on March 9th of each of 2027, 2028, 2029, and 2030, in each case subject to continuous service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent (25%) of the Stock Options shall vest on March 9th of each of 2027, 2028, 2029, and 2030, in each case subject to continuous service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 09, 2026 Filed Mar 12, 2026 01:17 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 109,885 | $0.00 Strike: $11.61 | $0.00 |
DisclosureSEC source: 0001104659-26-026587 · tm268588-8_4seq1.xml · derivative · entry 1 House David Duane · CIK 0002034219 · SVP, Finance, and PFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,885 Underlying: Common Stock · 109,885 shares Expires 2036-03-09 F1 · derivative.exercise_date: Twenty-five percent (25%) of the Stock Options shall vest on March 9th of each of 2027, 2028, 2029, and 2030, in each case subject to continuous service through the applicable vesting date. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:17 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001104659-25-010556 · tm255864-3_4seq1.xml · derivative · entry 1 House David Duane · CIK 0002034219 · SVP, Finance, and PFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-02-05 F1 · derivative.exercise_date: Twenty-five percent (25%) of the Stock Options shall vest on February 5th of each of 2026, 2027, 2028 and 2029, in each case subject to continuous service through the applicable vesting date. Read SEC document |
| October 02, 2024 Filed Oct 3, 2024 20:15 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001104659-24-105848 · tm2425499-2_4seq1.xml · derivative · entry 1 House David Duane · CIK 0002034219 · SVP, Finance, and PFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-10-02 F1 · derivative.exercise_date: The Options shall vest and become exercisable 25% on August 16th of each of 2025, 2026, 2027, and 2028, in each case subject to continuous service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.